RxDoctor Payments Data

Zagum Bhatti, MD

Vascular & Interventional Radiology · Port Authur, TXNPI 1053577890

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (33.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Angiodynamics, Inc. at 43.8% of the total. 2025 is the largest year on record at $32,220, 7.0 times the $4,635 reported in 2019. Among vascular & interventional radiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,728in general payments, 2019–2025

Across 298 payments — averaging $301.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$39K
  • Cook Incorporated$35K
  • Boston Scientific$6K
  • Medtronic$2K
  • Cook Medical LLC$1K
  • Astrazeneca UK Limited$1K
  • plus $4K from 17 others

What the payments were for

  • Consulting fees$7,2458%
  • Speaking & faculty fees$28,23031%
  • Travel & lodging$6,4327%
  • Food & beverage$9,82111%
  • Education$8,2509%
  • Other$29,75033%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,728 in reported general payments places this provider in the 90th percentile of 299 vascular & interventional radiology providers in Texas.

See all vascular & interventional radiology providers in Texas

Medicare billing

Part B allowed, 2024
$709,918
Medicare patients
163
Services billed
1,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban25$20,436
EliquisApixaban13$12,951
ClopidogrelClopidogrel Bisulfate83$614
Methylprednisolone32$238
Ciprofloxacin Hcl28$178
Naproxen34$103
Prednisone12$5

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$153$20,43625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 299 vascular & interventional radiology providers in Texas.

Other vascular & interventional radiology in Port Authur

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →